Latest Stories for Eagle Pharmaceuticals, Inc.dlvr.it Promoted Storieshttps://static.dlvr.it/images/d.pnghttps://static.dlvr.it/images/favicon.icotag:news.dlvr.it,2015-04-13:/organization/24902015-04-13T04:46:59-07:00<![CDATA[Eagle Pharmaceuticals Announces New Patent for Low-Sodium Bendamustine]]>tag:news.dlvr.it,2015-04-07:3625992015-04-07T07:51:01-07:00]]><![CDATA[Eagle Pharmaceuticals to Present at Needham & Company’s 14th Annual Healthcare Conference]]>tag:news.dlvr.it,2015-04-02:3557592015-04-02T13:30:09-07:00]]><![CDATA[Eagle Pharmaceuticals Announces Pricing of Public Offering of Common Stock]]>tag:news.dlvr.it,2015-03-17:3556752015-03-17T06:05:41-07:00]]><![CDATA[Eagle Pharmaceuticals Announces Commencement of Public Offering of Common Stock]]>tag:news.dlvr.it,2015-03-16:3543642015-03-16T13:01:16-07:00]]><![CDATA[FDA Grants Seven Years’ Market Exclusivity to Eagle Pharmaceuticals’ Ryanodex for the Treatment of Malignant Hyperthermia]]>tag:news.dlvr.it,2015-02-23:3353242015-02-23T07:24:02-08:00]]><![CDATA[Eagle Pharmaceuticals, Inc. Reports Financial Results for Three Month Period Ended December 31, 2014]]>tag:news.dlvr.it,2015-02-17:3391052015-02-17T13:01:40-08:00]]><![CDATA[Eagle Pharmaceuticals to Hold Conference Call at 8:30 a.m. EST Today to Discuss Licensing Agreement with Teva to Commercialize Eagle’s Rapid Infusion Bendamustine]]>tag:news.dlvr.it,2015-02-17:3454912015-02-17T04:05:08-08:00]]><![CDATA[Eagle Pharmaceuticals, Inc. Announces Change in Fiscal Year End]]>tag:news.dlvr.it,2015-01-20:3428832015-01-20T06:20:22-08:00]]><![CDATA[Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Financial Results]]>tag:news.dlvr.it,2014-12-17:3166332014-12-17T04:38:01-08:00]]><![CDATA[Eagle Pharmaceuticals to Discuss 2014 Fourth Quarter and Year-End Financial Results on December 17, 2014]]>tag:news.dlvr.it,2014-12-04:3298922014-12-04T14:56:01-08:00Eagle Pharmaceuticals to Discuss 2014 Fourth Quarter and Year-End Financial Results on December 17, 2014]]><![CDATA[Eagle Pharmaceuticals to Present at Piper Jaffray 2014 Healthcare Conference]]>tag:news.dlvr.it,2014-11-20:3151252014-11-20T07:01:32-08:00Eagle Pharmaceuticals to Present at Piper Jaffray 2014 Healthcare Conference]]><![CDATA[Eagle Pharmaceuticals Reports Positive Outcomes from Clinical Trial of Bendamustine HCl Product Delivered via Low-Volume, Rapidly Infused Admixture]]>tag:news.dlvr.it,2014-11-10:3145162014-11-10T04:33:01-08:00
Data indicate that Eagle’s Bendamustine HCl Product, Rapidly Infused
in a Low Volume Admixture, is Bioequivalent to Teva’s In-Market Branded
Product (Treanda®)
Safety Profile of Eagle’s Product is Comparable to Treanda
USPTO has Allowed Eagle’s Product Patent for Low-Volume, Short
Infusion Time Administration
]]><![CDATA[Eagle Pharmaceuticals to Present at Stifel 2014 Healthcare Conference]]>tag:news.dlvr.it,2014-11-07:3248132014-11-07T06:40:01-08:00]]><![CDATA[Eagle Pharmaceuticals to Present at 21st Annual NewsMakers in the Biotechnology Industry Investment Conference]]>tag:news.dlvr.it,2014-09-23:3029382014-09-23T07:41:09-07:00]]><![CDATA[Eagle Pharmaceuticals Announces That Teva Requests a Motion to Dismiss with Prejudice in Its Bendamustine Patent Infringement Lawsuit]]>tag:news.dlvr.it,2014-09-17:3011232014-09-17T05:06:02-07:00
Second Lawsuit Filed Based on Cephalon’s Newly Issued Patent
]]>
]]>